tiragolumab + atezolizumab + carboplatin + etoposide

Combination of **tiragolumab, atezolizumab, carboplatin, and etoposide** is an investigational anti-cancer regimen evaluated primarily for certain **solid tumors, particularly small cell lung cancer (SCLC)** and **non-small cell lung cancer (NSCLC)**. - *Tiragolumab* is a monoclonal antibody (IgG1/kappa) targeting the immune checkpoint TIGIT (T-cell immunoreceptor with Ig and ITIM domains), designed to block its interaction with PVR (CD155), thus lifting tumor-induced immune suppression and enhancing T cell and NK cell anti-tumor activity[7][1][2][3]. - *Atezolizumab* is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), preventing its interaction with PD-1 and B7.1 receptors, thereby restoring anti-tumor T cell responses[7][1][2][3]. - *Carboplatin* is a cytotoxic platinum-based chemotherapeutic agent that induces DNA crosslinks and cell death in dividing cells. - *Etoposide* is a topoisomerase II inhibitor that prevents DNA unwinding and replication, leading to apoptosis in proliferating cells. This quadruple regimen is researched for its potential to combine immunotherapy with traditional chemotherapy, aiming for additive or synergistic anti-tumor effects, particularly as first-line therapy in extensive-stage SCLC. **Developed and manufactured by Roche/Genentech, with carboplatin and etoposide produced by multiple generic manufacturers.**

Brand names

Tecentriq

Other names

tiragolumab plus atezolizumab plus carboplatin plus etoposide